Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 8, 2009 - Issue 3
Submit an article Journal homepage
88
Views
2
CrossRef citations to date
0
Altmetric
Reviews

Non-investigational antiarrhythmic drugs: long-term use and limitations

Knut Gjesdal Professor of Cardiology University of Oslo, Ullevål University Hospital, Department of Cardiology, Oslo, Norway +47 22119448; +47 22119960; [email protected]
, MD PhD
Pages 345-355 | Published online: 12 May 2009

Bibliography

  • Nattel S, Singh BN. Evolution, mechanisms, and classification. of antiarrhythmic drugs: focus on class III actions. Am J Cardiol 1999;84:11R-19R
  • Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8
  • Greenberg H, Dwyer E, Hochman J, et al. Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. Br Heart J 1995;74:631-5
  • Singarayar S, Bursill J, Wyse K, et al. Extracellular acidosis modulates drug block of Kv4.3 currents by flecainide and quinidine. J Cardiovasc Electrophysiol 2003;14:641-50
  • Fornieles-Pérez H, Montoya-García M, Levine P, Sanz O. Documentation of acute rise in ventricular capture thresholds associated with flecainide acetate. Pacing Clin Electrophysiol 2002;25:871-2
  • Dopp AL, Miller JM, Tisdale JE. Effect of drugs on defibrillation capacity. Drugs 2008;68:607-30
  • Gasparini M, Priori S, Mantica M, et al. Flecainide test in Brugada syndrome: a reproducible but risky tool. Pacing Clin Electrophysiol 2003;26:338-41
  • Tjandra-Maga TB, van Hecken A, van Melle P, et al. Altered pharmacokinetics of oral flecainide by cimetidine. Br J Clin Pharmacol 1986;22:108-10
  • Anderson JL, Jolivette DM, Fredell PA. Summary of efficacy and safety of flecainide for supraventricular arrhythmias. Am J Cardiol 1988;62:62D-66D
  • Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106-16
  • Dumaine R, Antzelevitch C. Disopyramide: although potentially life-threatening in the setting of long QT, could it be life-saving in short QT syndrome? J Mol Cell Cardiol 2006;41:421-3
  • Gibson D, Sowton E. The use of beta adrenergic receptor blocking drugs in dysrhythmias. Prog Cardiovasc Dis 1969;12:16-39
  • Singh BN. Beta-adrenergic blockers as antiarrhythmic and antifibrillatory compounds: an overview. J Cardiovasc Pharmacol Ther 2005;10(Suppl 1):S3-14
  • Kuhlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, doubleblind, placebo-controlled study. J Am Coll Cardiol 2000;36:139-46
  • Kennedy HL. Beta-blocker prevention of proarrhythmia and proischemia: clues from CAST, CAMIAT, and EMIAT. Cardiac Arrhythmia Suppression Trial. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. European Myocardial Infarct Amiodarone Trial. Am J Cardiol 1997;80:1208-11
  • Nagele H, Bohlmann M, Eck U, et al. Combination therapy with carvedilol and amiodarone in patients with severe heart failure. Eur J Heart Fail 2000;2:71-9
  • Ogunyankin KO, Singh BN. Mortality reduction by antiadrenergic modulation of arrhythmogenic substrate: significance of combining beta blockers and amiodarone. Am J Cardiol 1999;84:76R-82R
  • Shantsila E, Watson T, Lip GY. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias. Europace 2007;9(Suppl 4):37-44
  • Singh BN, Vaughan Williams EM. A third class of antiarrhythmic action. Effects on atrial and ventricular action potentials and other pharmacologic actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 1970;39:675-87
  • Hohnloser SH, Woosley RL. Sotalol. N Engl J Med 1994;331:31-8. Available from: http://content.nejm.org/cgi/content/full/331/1/31
  • Remme CA, Bezzina CR. Genetic modulation of cardiac repolarization reserve. Heart Rhythm 2007;4:608-10
  • Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone. Heart Rhythm 2007;4:1250-9
  • Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007;298:1312-22
  • Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004;4:281-97
  • Fenster PE, White NW Jr, Hanson CD. Pharmacokinetic evaluation of the digoxin-amiodarone interaction. J Am Coll Cardiol 1985;5:108-12
  • Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999;341:1447-57
  • Ito S, Woodland C, Harper PA, et al. The mechanism of the verapamil-digoxin interaction in renal tubular cells (LLC-PK1). Life Sci 1993;53:399-403
  • Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 2006;26:1601-7
  • Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006;113:2556-64
  • Gjesdal K, Feyzi J, Olsson SB. Digitalis – a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. Heart 2008;94:191-6
  • Hallberg P, Lindbäck J, Lindahl B, et al. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol 2007;63:959-71
  • The AFFIRM Investigators. Relationships between sinus rhythm, treatment and survival in the atrial fibrillation follow-up investigation of rhythm management [AFFIRM] study. Circulation 2004;109:1509-13
  • Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias–executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines [Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias]. Circulation 2003;108:1871-909
  • Berruezo A, Díez GR, Berne P, et al. Low exposure radiation with conventional guided radiofrequency catheter ablation in pregnant women. Pacing Clin Electrophysiol 2007;30:1299-302
  • Natale A, Davidson T, Geiger MJ, Newby K. Implantable cardioverter-defibrillators and pregnancy: a safe combination? Circulation 1997;96:2808-12
  • U.S. Food and Drug Administration, Center for drug evaluation and research. Pregnancy and lactation labelling. Available from: http://www.fda.gov/cder/regulatory/pregnancy_labeling/default.htm [Last accessed 14 March 2009]
  • Qasqas SA, McPherson C, Frishman WH, et al. Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation. Cardiol Rev 2004;12:201-21
  • Lee KW, Badhwar N, Scheinman MM. Supraventricular tachycardia–part I. Curr Probl Cardiol 2008;33:467-546
  • Lee KW, Badhwar N, Scheinman MM. Supraventricular tachycardia-Part II: history, presentation, mechanism, and treatment. Curr Probl Cardiol 2008;33:557-622
  • Mauritson DR, Winniford MD, Walker WS, et al. Oral verapamil for paroxysmal supraventricular tachycardia: a long-term, double-blind randomized trial. Ann Intern Med 1982;96:409-12
  • Winniford MD, Fulton KL, Hillis LD. Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double-blind comparison of digoxin, propranolol and verapamil. Am J Cardiol 1984;54:1138-9
  • Yee R, Gulamhusein SS, Klein GJ. Combined verapamil and propranolol for supraventricular tachycardia. Am J Cardiol 1984;53:757-63
  • Sellers TD Jr, Bashore TM, Gallagher JJ. Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. Circulation 1977;56:260-7
  • Spurrell RA, Krikler DM, Sowton E. Effects of verapamil on electrophysiological properties of anomalous atrioventricular connexion in Wolff-Parkinson-White syndrome. Heart 1974;36:256-64
  • Henthorn RW, Waldo AL, Anderson JL, et al. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. Circulation 1991;83:119-25
  • Hellestrand KJ. Efficacy and safety of long-term oral flecainide acetate in patients with responsive supraventricular tachycardia. Am J Cardiol 1996;77:83A-8A
  • Kim SS, Smith P, Ruffy R. Treatment of atrial tachyarrhythmias and preexcitation syndrome with flecainide acetate. Am J Cardiol 1988;62:29D-34D
  • Spurrell RA, Thorburn CW, Camm J, et al. Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrioventricular pathway in Wolff-Parkinson-White syndrome. Br Heart J 1975;37:861-7
  • Brugada P, Wellens HJJ. Effects of intravenous and oral disopyramide on paroxysmal atrioventricular nodal tachycardia. Am J Cardiol 1984;53:88-92
  • Kunze KP, Schlüter M, Kuck KH. Sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 1987;75:1050-7
  • Mitchell LB, Wyse DG, Duff HJ. Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 1987;76:810-8
  • Alboni P, Shantha N, Pirani R, et al. Effects of amiodarone on supraventricular tachycardia involving bypass tracts. Am J Cardiol 1984;53:93-8
  • Goldberg AS, Bathina MN, Mickelsen S, et al. Long-term outcomes on quality-of-life and health care costs in patients with supraventricular tachycardia [radiofrequency catheter ablation versus medical therapy]. Am J Cardiol 2002;89:1120-3
  • Kim RJ, Iwai S, Markowitz SM, et al. Clinical and electrophysiological spectrum of idiopathic ventricular outflow tract arrhythmias. J Am Coll Cardiol 2007;49:2035-43
  • Katz G, Arad M, Eldar M. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond. Curr Probl Cardiol 2009;34:9-43
  • Swan H, Laitinen P, Kontula K, Toivonen L. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol 2005;16:162-6
  • Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic study versus electrocardiographic monitoring investigators. N Engl J Med 1993;329:452-8
  • Passman R, Kadish A. Sudden death prevention with implantable devices. Circulation 2007;116:561-71
  • Kühlkamp V, Mewis C, Mermi J, et al. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol 1999;33:46-52
  • Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. D,l-sotalol implantable cardioverter-defibrillator study group. N Engl J Med 1999;340:1855-62
  • Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: The OPTIC study: a randomized trial. JAMA 2006;295:165-71
  • Ferreira-González I, Dos-Subirá L, Guyatt GH. Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review. Eur Heart J 2007;28:469-77
  • Blaauw Y, Crijns HJGM. Treatment of atrial fibrillation. Heart 2008;94:1342-9
  • Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042-6
  • Ariansen I, Gjesdal K, Abdelnoor M, et al. Quality of life, exercise capacity and comorbidity in old patients with permanent atrial fibrillation. J Atrial Fibrillation 2008;1:202-8
  • Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines [Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation]. Eur Heart J 2006;27:1979-2030
  • Fauchier L, Pierre B, de Labriolle A, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008;51:828-35
  • Yin Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006;27:1841-6
  • Komatsu T, Ozawa M, Tachibana H, et al. Combination therapy with amiodarone and enalapril in patients with paroxysmal atrial fibrillation prevents the development of structural atrial remodeling. Int Heart J 2008;49:435-47
  • Anderson JL, Gilbert EM, Alpert BL, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide supraventricular tachycardia study group. Circulation 1989;80:1557-70
  • Patten M, Maas R, Bauer P, et al. Suppression of paroxysmal atrial tachyarrhythmias–results of the SOPAT trial. Eur Heart J 2004;25:1395-404
  • Steeds RP, Birchall AS, Smith M, Channer KS. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart 1999;82:170-5
  • Alboni P, Botto GL, Baldi N. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med 2004;351:2384-91
  • Gjesdal K, Vist GE, Bugge E, et al. Curative ablation for atrial fibrillation – a systematic review. Scand Cardiovasc J 2008;42:3-8
  • McKenna C, Palmer S, Rodgers M, et al. Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the UK. Heart 2009;95:542-9
  • Khargi K, Keyhan-Falsafi A, Hutten BA, et al. Surgical treatment of atrial fibrillation: a systematic review. Herzschrittmacherther Elektrophysiol 2007;18:68-76
  • Boos CJ, More RS, Carlsson J. Persistent atrial fibrillation: rate control or rhythm control. Rate control is not inferior to rhythm control. BMJ 2003;326:1411-2
  • Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004;43:1201-8
  • Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management [AFFIRM] Study. Circulation 2004;109:1509-13
  • Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008;118:2498-505
  • Louagie Y, Buche M, Eucher P, et al. Improved patient survival with concomitant Cox Maze III procedure compared with heart surgery alone. Ann Thorac Surg 2009;87:440-6
  • Roy D, Talajic M, Nattel S, et al. Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-77
  • Cosio FG, Aliot E, Botto GL, et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace 2008;10:21-7
  • Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2007;4:CD005049. DOI: 10.1002/14651858.CD005049.pub2
  • Pedersen OD, Brendorp B, Elming H, et al. Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study Card Electrophysiol Rev 2003;7:220-4
  • Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78
  • Gulizia M, Mangiameli S, Orazi S, et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias [PITAGORA] trial. Am Heart J 2008;155:100-7
  • Kühlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000;36:139-46
  • Benditt DG, Williams JH, Jin J, et al. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. D,l-Sotalol Atrial Fibrillation/Flutter Study Group. Am J Cardiol 1999;84:270-7
  • Wanless RS, Anderson K, Joy M, Joseph SP. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J 1997;133:441-6
  • Capucci A, Botto G, Molon G, et al. The Drug And Pace Health cliNical Evaluation [DAPHNE] study: a randomized trial comparing sotalol versus beta-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker. Am Heart J 2008;156:373.e1-8
  • Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian trial of atrial fibrillation investigators. N Engl J Med 2000;342:913-20
  • Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-72
  • Ahmed S, Rienstra M, Crijns HJ. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA 2008;300:1784-92
  • De Simone A, De Pasquale M, De Matteis C, et al. Verapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion [VEPARAF Study]. Eur Heart J 2003;24:1425-9
  • Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation:a meta-analysis. Circulation 2000;101:1138-44
  • Wellens HJ. Contemporary management of atrial flutter. Circulation 2002;106:649-52
  • Natale A, Newby KH, Pisano E, et al. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol 2000;35:1898-904
  • Belz GG, Breithaupt-Grögler K, Osowski U. Treatment of congestive heart failure–current status of use of digitoxin. Eur J Clin Invest 2001;31(Suppl 2):10-7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.